Site search

Clear filter
2923 results for '' found
First In Human Feasibility Clinical Study Evaluating the Safety of the XPD System for Periosteal Distraction [PD] (ACTRN12625000159459)
/
A Phase 1b/2 Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP-104GI in Adults with Eosinophilic Esophagitis [RESOLVE] (NCT05608681)
/
Assessing cognitive trajectories in Progressive Supranuclear Palsy using remote computerized reaction time tasks (Trial Not Registered)
/
Memorandum for sponsors December 2025 pdf
Memo_for_sponsors_re_transition_to_Bayside_Health_151225.pdf
Alfred Health - Emergency and Trauma Centre (Easy Read) PDF
https://app.prompt.org.au/download/258119?code=759b5178-7c15-474c-bb1b-45cefbed2828
Alfred Health GP News - December 2025 pdf
Alfred_Health_GP_News_-_December_2025.pdf
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC (NCT06881784)
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC (NCT06881784)
/
A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa [BRIGHTE
A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa [BRIGHTE
/
Assessing the impact of atrial fibrillation and catheter ablation on sexual function: an observational study (Trial Not Registered)
Assessing the impact of atrial fibrillation and catheter ablation on sexual function: an observational study (Trial Not Registered)
/
A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic
A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic
/
11 12 13 14 15